{
 "Herold2002": {
  "doi": "10.1056/NEJMoa012864",
  "title": "Anti-CD3 Monoclonal Antibody in New-Onset Type 1 Diabetes Mellitus",
  "venue": "NEJM",
  "year": 2002,
  "note": "First teplizumab RCT, new-onset T1D \u2014 preserved C-peptide"
 },
 "Keymeulen2005": {
  "doi": "10.1056/NEJMoa043980",
  "title": "Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes",
  "venue": "NEJM",
  "year": 2005,
  "note": "Otelixizumab (Belgian Diabetes Registry) parallel anti-CD3"
 },
 "Herold2013_AbATE": {
  "doi": "10.2337/db13-0345",
  "title": "Teplizumab (Anti-CD3 mAb) Treatment Preserves C-Peptide Responses (AbATE)",
  "venue": "Diabetes",
  "year": 2013,
  "note": "AbATE trial \u2014 durable responders"
 },
 "Herold2019_TN10": {
  "doi": "10.1056/NEJMoa1902226",
  "title": "An Anti-CD3 Antibody, Teplizumab, in Relatives at Risk for Type 1 Diabetes",
  "venue": "NEJM",
  "year": 2019,
  "note": "TN-10 \u2014 median 2-yr delay of clinical onset; pivotal for approval"
 },
 "Sims2021_TN10ext": {
  "doi": "10.1126/scitranslmed.abc8980",
  "title": "Teplizumab improves and stabilizes beta cell function in at-risk (TN-10 extended)",
  "venue": "Sci Transl Med",
  "year": 2021,
  "note": "Extended follow-up: median delay ~3 yr"
 },
 "Goel2017_Nexvax2": {
  "doi": "10.1016/S2468-1253(17)30110-3",
  "title": "Epitope-specific immunotherapy targeting CD4+ T cells in coeliac disease (Nexvax2 Ph1)",
  "venue": "Lancet Gastroenterol Hepatol",
  "year": 2017,
  "note": "Two Ph1 RCTs; defined 3-peptide immunodominant epitope set"
 },
 "TyeDin2010": {
  "doi": "10.1126/scitranslmed.3001012",
  "title": "Comprehensive, quantitative mapping of T-cell epitopes in gluten",
  "venue": "Sci Transl Med",
  "year": 2010,
  "note": "Anderson/Tye-Din epitope hierarchy \u2014 scientific basis of Nexvax2"
 },
 "Truitt2019_Nexvax2": {
  "doi": "10.1111/apt.15435",
  "title": "Randomised clinical trial: a placebo-controlled study of subcutaneous or intradermal Nexvax2, an epitope-specific immunotherapy for coeliac disease",
  "venue": "Aliment Pharmacol Ther",
  "year": 2019,
  "note": "Ph1b fixed-dose escalation"
 },
 "Kelly2021_TAK101": {
  "doi": "10.1053/j.gastro.2021.03.014",
  "title": "TAK-101 Nanoparticles Induce Gluten-Specific Tolerance in Celiac Disease: A Randomized Trial",
  "venue": "Gastroenterology",
  "year": 2021,
  "note": "Phase 2a \u2014 reduced gluten-induced IFN-g+ T cells"
 },
 "Getts2012_TIMP": {
  "doi": "10.1038/nbt.2434",
  "title": "Microparticles bearing encephalitogenic peptides induce T-cell tolerance",
  "venue": "Nat Biotechnol",
  "year": 2012,
  "note": "Miller/Getts PLGA tolerogenic NP platform \u2014 TAK-101 precursor"
 },
 "ClementeCasares2016_Navacim": {
  "doi": "10.1038/nature16962",
  "title": "Expanding antigen-specific regulatory networks to treat autoimmunity with pMHC nanoparticles",
  "venue": "Nature",
  "year": 2016,
  "note": "Santamaria Navacim platform \u2014 pMHC-II NP -> TR1 cells; TRUE pMHC"
 },
 "Singha2017_Navacim": {
  "doi": "10.1038/nnano.2017.56",
  "title": "Peptide-MHC-based nanomedicines for autoimmunity",
  "venue": "Nat Nanotechnol",
  "year": 2017,
  "note": "Navacim mechanism extension"
 },
 "Ludvigsson2012_GAD": {
  "doi": "10.1056/NEJMoa1107096",
  "title": "GAD65 Antigen Therapy in Recently Diagnosed Type 1 Diabetes",
  "venue": "NEJM",
  "year": 2012,
  "note": "Ph3 European trial \u2014 missed primary endpoint"
 },
 "Ludvigsson2021_DIAGNODE2": {
  "doi": "10.2337/dc21-0318",
  "title": "Intralymphatic GAD-alum + Vitamin D in T1D (DIAGNODE-2)",
  "venue": "Diabetes Care",
  "year": 2021,
  "note": "Missed overall endpoint; HLA DR3-DQ2 subgroup benefit -> precision pivot"
 },
 "AlhadjAli2017_MonoPepT1De": {
  "doi": "10.1126/scitranslmed.aaf7779",
  "title": "Metabolic and immune effects of immunotherapy with proinsulin peptide (MonoPepT1De)",
  "venue": "Sci Transl Med",
  "year": 2017,
  "note": "Ph1a proinsulin C19-A3 \u2014 safety + mechanistic tolerance"
 },
 "Chataway2018_ATXMS": {
  "doi": "10.1212/WNL.0000000000005118",
  "title": "Effects of ATX-MS-1467 immunotherapy over 16 weeks in relapsing MS",
  "venue": "Neurology",
  "year": 2018,
  "note": "Apitope MBP peptide \u2014 reduced Gd-enhancing lesions"
 },
 "Serra2019_review": {
  "doi": "10.1038/s41587-019-0015-4",
  "title": "Antigen-specific therapeutic approaches for autoimmunity",
  "venue": "Nat Biotechnol",
  "year": 2019,
  "note": "Santamaria review \u2014 field framing"
 }
}